As of May 22
| +2.26 / +3.15%|
The 17 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 56.00, with a high estimate of 118.00 and a low estimate of 42.00. The median estimate represents a -24.25% decrease from the last price of 73.93.
The current consensus among 18 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.